Inhalopédia | Inhalers

Class
- Inhaled corticosteroid (ICS)
  Long-acting muscarinic antagonist (LAMA)
  Long-acting beta-2 agonist (LABA)
Active ingredient
- Fluticasone furoate
- Umeclidinium (as bromide)
- Vilanterol (as trifenatate)
Device
- Ellipta®
Inhalers techniques and maintenance
Age
- 18 +
Typical use
- Asthma
  uncontrolled on high doses ICS + LABA
Asthma management principles
- COPD (100/62.5/25 mcg only)
  exacerbation on dual bronchodilation (LAMA/LABA)
COPD management principles
Marketed strength
- 100/62,5/25 mcg
- 200/62,5/25 mcg
Number of doses
- 30 doses
Dose indicator
- Yes | Numerical
Usual adult dosage
- Medium | 100/62.5/25 mcg – 1 inh QD
  High | 200/62.5/25 mcg – 1 inh QD
ICS dosing
Usual pediatric dosage
- -
Required inspiratory flow
- > 30 - 60 L/min
  Medium-low internal resistance (R2)
Inspiratory flows
Public coverage
- 100/62.5/25 mcg | All provinces | Restricted Benefit with criteria
  200/62.5/25 mcg | All provinces | Not a Benefit
Provincial coverage criteria
Advantages
- Once daily dosing
- All the daily medication in one inhaler
- Easy handling
Disadvantages
- More dysphonia
- Taste that can be unpleasant
- Lip sealing difficult for some older patients
Side effects

Product monograph

Download

Trelegy®